Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is funded by PER^®.

Targeting Folate Receptor-α in Ovarian Cancer

Release Date: March 24, 2021
Expiration Date: March 24, 2022

Activity Overview

This continuing medical education (CME) activity is designed to inform health care providers involved in the clinical care of patients with ovarian cancer of emerging data surrounding the folate receptor-α (FRα) therapies for the treatment advanced ovarian cancer. This in-depth program will cover a brief review and recent updates regarding the development of FRα-targeted therapy, including key data and potential clinical implications for the treatment landscape for ovarian cancer.

Acknowledgement of Commercial Support

This activity is funded by PER^®.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Describe the physiologic function of folate receptor-α (FRα) in ovarian cancer
Explain the rationale for targeting FRα as a mechanism for treating ovarian cancer
Assess key data from ongoing clinical trials evaluating emerging FRα-targeting agents for the treatment of ovarian cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Kathleen Moore, MD, MS
Virginia Kerley Cade Chair in Developmental Therapeutics
Associate Director Clinical Research and Director
Early Phase Drug Development
Stephenson Oklahoma Cancer Center
Oklahoma City, OK

Disclosures: Grant/Research Support: PTC Therapeutics, Merck, Lilly. Consultant: Advisory boards for Aravive, Astra Zeneca, AbbVie, Eisai, GSK/Tesaro, Genentech/Roche, Immunogen, Elevar, Myriad, Mersana, Merck, VBL Therapeutics, Corcept.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

This activity was written by PER^® editorial staff under faculty guidance and review. The Q&A portion of the activity was transcribed from a recorded interview with the faculty and edited by faculty and PER^® editorial staff for clarity.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.